Hospital

Bepirovirsen shows promise as a groundbreaking treatment for chronic hepatitis B, achieving significant functional cure rates in recent phase 3 trials.

Discover how the new PREVENT equations enhance cardiovascular risk assessments, improving patient screenings and prevention strategies for diverse populations.

A recent study shows thyroid surgery can be safely performed on patients post–COVID-19 infection with careful screening, ensuring patient safety and positive outcomes.

Psychiatric pharmacists enhance substance use disorder (SUD) care through interdisciplinary collaboration, advocating for policy changes to improve patient outcomes and access to treatment.

Psychiatric pharmacists enhance opioid use disorder treatment through innovative protocols, collaboration, and education.

Psychiatric pharmacists enhance substance use disorder (SUD) care by managing medications and treatment strategies.

A severe yet often overlooked coinfection with hepatitis B, hepatitis D progresses rapidly—but new therapies are beginning to reshape a long-limited treatment landscape.

Researchers develop a novel therapy combining molecular glues and KRAS inhibitors, showing promise in treating KRAS-mutant non–small cell lung cancer.

Research reveals that adults who were hospitalized with RSV experience significant long-term health issues, impacting quality of life and physical function.

Effective SCD pain management requires an integrated, multimodal strategy across outpatient and inpatient settings.

The FDA approved mitapivat, the first oral therapy for thalassemia due to anemia, offering hope for patients with transfusion-dependent and non–transfusion-dependent forms.

UCSF pharmacists unveil an AI tool, Foghorn, enhancing investigational drug trials by streamlining processes and minimizing delays in drug development.

Narsoplimab gains FDA approval for treating transplant-associated thrombotic microangiopathy, showing promising survival rates in high-risk patients.

Lowering blood glucose levels significantly reduces heart disease risks in prediabetes, offering new hope for prevention and management strategies.

Sacituzumab govitecan shows promising overall survival trends in HR+/HER2− metastatic breast cancer, despite not meeting primary progression-free survival goals.

The FDA's 2025 biosimilar approvals enhanced treatment options for chronic diseases, improving accessibility and affordability for patients and health care providers.

Continuous glucose monitoring (CGM) significantly reduces the risk of high birth weight in babies born to mothers with gestational diabetes.

Discover the vital role of oncology pharmacists in cancer care, exploring their daily challenges, responsibilities, and impact on patient outcomes.

Orforglipron shows promise in maintaining weight loss for individuals transitioning from injectable therapies, offering a convenient oral option for obesity management.

In patients with ST-segment elevation myocardial infarction, lowering low-density lipoprotein cholesterol to optimal levels prevented neoatherosclerosis, a complication following stent implantation.

Prateek Bhatia discusses optimizing staffing and workflows in infusion centers to enhance patient care and reduce delays in treatment.

Tracking your net worth monthly can shift your financial mindset and build lasting wealth.

Researchers uncover how type 2 innate lymphoid (ILC2) and T helper 2 (Th2) cells in allergic asthma survive toxic environments, revealing potential new therapeutic strategies for treatment.

IV compounding robotics and next-generation dispensing technology enhance pharmacy workflows, boost staff engagement, and improve patient care outcomes.

The novel agent has demonstrated efficacy in symptomatic and less severe patients with obstructive hypertrophic cardiomyopathy in thorough phase 3 clinical trials.

Ribociclib shows higher early treatment modifications than palbociclib in HR+/HER2– breast cancer, emphasizing the need for proactive toxicity management.

Heidi De Souza, MPH, reveals low RSV vaccine uptake among older adults, highlighting disparities and barriers that hinder access and awareness post-FDA approval.